118 articles, page 2 of 10
Newest first
The number of GLP-1 medications available for weight loss has expanded significantly in recent years, and the decision of which one to use is no longer straightforward.
By Harbor Health Team
Most people who lose weight gain it back. That statement is supported by decades of clinical research showing that 80% to 90% of individuals who achieve meaningful weight loss eventually return to their starting weight or close to it.
By Harbor Health Team
Starting a GLP-1 medication for weight loss is a clinical decision, and the lab work surrounding that decision is just as important as the prescription itself.
By Harbor Health Team
Semaglutide has reshaped the landscape of medical weight loss. Clinical trials demonstrate an average body weight reduction of 14.9% over 68 weeks, and many patients experience rapid, visible results within the first few months of treatment.
By Harbor Health Team
Tirzepatide's dosing schedule is one of the most important aspects of treatment that patients need to understand before starting the medication.
By Harbor Health Team
Liraglutide was the first GLP-1 receptor agonist approved specifically for weight management, reaching the market as Saxenda in 2014, several years before semaglutide (Wegovy) or tirzepatide (Zepbound) became available.
By Harbor Health Team
For the estimated 37 million Americans living with type 2 diabetes, the relationship between blood sugar management and weight loss has always been frustratingly circular: excess weight drives insulin resistance, insulin resistance makes weight loss harder, and many diabetes medications actually cause weight gain as a side effect.
By Harbor Health Team
"How much weight will I lose?" is the first question most patients ask when considering tirzepatide, and it deserves a thorough, evidence-based answer.
By Harbor Health Team
Tirzepatide's dosing schedule is one of the most important aspects of treatment that patients need to understand before starting the medication.
By Harbor Health Team
You've been taking Contrave for months. The cravings quieted down, the scale moved in the right direction, and for the first time in a long time, food stopped running your day.
By Harbor Health Team
Tirzepatide is the first medication in its class to target two incretin hormones simultaneously - GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
By Harbor Health Team
Standing on the bathroom scale tells you a number, but that number rarely tells the full story about your health.
By Harbor Health Team
